Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 4Leukemia, Myelomonocytic, Chronic 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Cytopenia 2Anemia, Refractory, with Excess of Blasts 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Splenomegaly 1Polycythemia Vera 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Anemia, Refractory 1Anemia 1

Interventions

fludarabine phosphate 27Peripheral Blood Stem Cell Transplantation 25Cyclophosphamide 24Busulfan 17Tacrolimus 16Whole-Body Irradiation 15Mycophenolic Acid 14Methotrexate 12Cyclosporine 12Antilymphocyte Serum 10Melphalan 7Filgrastim 7Etoposide 7fludarabine 6Radiotherapy 5Decitabine 5Carboplatin 5ruxolitinib 4Topotecan 4Methylprednisolone 4Flow Cytometry 4Cytarabine 4Thiotepa 3Imatinib Mesylate 3Cytogenetic Analysis 3Alemtuzumab 3veliparib 2merphos 2liposomal amphotericin B 2aldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Polycythemia Vera × ON 01910 × Other hematologic neoplasm × Clear all
NCT01167166 2017-06-26

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Traws Pharma, Inc.

Phase 1/2 Completed
30 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡